

ASX Announcement

ASX Appendix 4C Quarterly Cash Flow Report For the quarter ended 30 June 2014

Sydney, Thursday, 31 July 2014: OncoSil Medical Ltd (ASX: OSL) attaches the Company's Appendix 4C Quarterly Cash Flow Report for the period ended 30 June 2014.

Net operating cash flow for the quarter was \$3.282 million which included \$2.391 million of prepayments for future expenses. The company elected to prepay these expenses, after consultation with several key suppliers, for Treasury, Financial Management and Tax Planning reasons.

For further information, please contact the person noted below, or visit the Company website at www.oncosil.com.au.

ENDS

Contact:

Dr Neil Frazer
Chief Executive Officer and Managing Director
neil.frazer@oncosil.com.au
T +61 2 9223 3344
Twitter: @Dr_Neil_Frazer

About OncoSil Medical Ltd

OncoSil Medical Ltd is a clinical-stage Australian biotechnology company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical Ltd's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a bio-silica P32(phosphorous) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil™ has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumors outside of pancreatic cancer. FDA and EMA approval for pancreatic cancer is the core focus of OncoSil Medical Ltd.

Pancreatic Cancer

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2010 280,000 people globally were diagnosed with pancreatic cancer including 43,140 Americans, 70,000 Europeans and 2,546 in Australia. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 6%. The world-wide market for pancreatic drugs is projected by Global Industry Analysis to exceed US\$1.2bn by 2015.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

OncoSil Medical Limited

ABN

89 113 824 141

Quarter ended ("current quarter")

30 June 2014

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (12 months) \$A'000
1.1	Receipts from customers	0	0
1.2	Payments for (a) staff costs	(181)	(555)
	(b) advertising and	0	(1)
	marketing		
	(c) research and	(3,008)	(4,279)
	development		
	(d) leased assets	0	0
	(e) other working capital	(542)	(1,805)
1.3	Dividends received	41	58
1.4	Interest and other items of a similar nature received	52	204
1.5	Interest and other costs of finance paid	0	0
1.6	Income taxes refunded	315	315
1.7	Other (provide details if material)	41	42
Net operating cash flows		(3,282)	(6,021)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (12 months) \$A'000
1.8 Net operating cash flows (carried forward)	(3,282)	(6,021)
Cash flows related to investing activities		
1.9 Payment for acquisition of:	0	0
(a) businesses (item 5)	0	0
(b) equity investments	0	0
(c) intellectual property	0	0
(d) physical non-current assets	(1)	(15)
(e) other non-current assets	0	0
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	0	0
(b) equity investments	0	0
(c) intellectual property	0	0
(d) physical non-current assets	0	0
(e) other non-current assets	0	0
1.11 Loans to other entities	0	0
1.12 Loans repaid by other entities	0	0
1.13 Other (provide details if material)	0	0
	(1)	(15)
Net investing cash flows		
1.14 Total operating and investing cash flows	(3,283)	(6,036)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	0	10,326
1.16 Proceeds from sale of forfeited shares	0	0
1.17 Proceeds from borrowings	0	0
1.18 Repayment of borrowings	0	0
1.19 Dividends paid	0	0
1.20 Other – Share Issue Costs	0	(492)
	0	9,834
Net financing cash flows		
Net increase (decrease) in cash held	(3,283)	3,798
1.21 Cash at beginning of quarter/year to date	10,336	3,510
1.22 Exchange rate adjustments	(25)	(280)
1.23 Cash at end of quarter	7,028	7,028

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	95
1.25	Aggregate amount of loans to the parties included in item 1.11	0
1.26	Explanation necessary for an understanding of the transactions The amount disclosed is all payments made to directors and related parties in the quarter. The full amount is included in the total at 1.2(a).	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

NIL

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

NIL

Financing facilities available

Add notes as necessary for an understanding of the position.

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	n/a	n/a
3.2 Credit standby arrangements	n/a	n/a

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	495	1,076
4.2	Deposits at call	6,533	9,260
4.3	Bank overdraft	0	0
4.4	Other (provide details)	0	0
Total: cash at end of quarter (item 1.23)		7,028	10,336

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	n/a	n/a
5.2	Place of incorporation or registration	n/a	n/a
5.3	Consideration for acquisition or disposal	n/a	n/a
5.4	Total net assets	n/a	n/a
5.5	Nature of business	n/a	n/a

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:


 (Director/Company Secretary)

Date: 31/07/2014

Print name: Peter Casey

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.